Polycystic Kidney Diseases: all 158 studies

Page 1 of 2. Open to participants first (21), then studies with results posted, then the rest; newest registration first within each.

• Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney DiseaseRecruitingNCT07454174Not applicable
• STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney DiseaseRecruitingNCT07280585Phase 3
• The Factors Affecting IPP in Peritoneal Dialysis Patients with Polycystic Kidney DiseaseEnrolling by invitationNCT06841224
• Analysis of Patients With Autosomal Dominant Polycystic KidneyRecruitingNCT06759142
• Amnioinfusion for Fetal Renal FailureRecruitingNCT06728228Not applicable
• Study to Evaluate the Drug-drug Interaction of JMKX003142 in Healthy SubjectsNot yet recruitingNCT06658964Phase 1
• Shared Decision Making for Choosing Autosomal DOminant Polycystic Kidney Disease TreatmentRecruitingNCT06618638Not applicable
• Congenital Hepatic Fibrosis and Autosomal Recessive Polycystic Kidney Disease in Children at Sohag University HospitalRecruitingNCT06601829
• Glucagon-Like Peptide-1 Receptor Agonist in ADPKDRecruitingNCT06582875Phase 2
• Well-Formulated Ketogenic Diet Polycystic Kidney DiseaseRecruitingNCT06325644Not applicable
• Treat Autosomal Dominant Polycystic Kidney Disease With Oral Ketone Ester?Not yet recruitingNCT06100133Phase 2
• National Registry of Rare Kidney DiseasesRecruitingNCT06065852
• Atorvastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney DiseaseEnrolling by invitationNCT05870007Phase 2
• A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver DiseaseRecruitingNCT05478083Phase 2
• A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)RecruitingNCT04782258Phase 3
• ADPKD Patient RegistryRecruitingNCT04039061
• Early PKD Observational Cohort StudyRecruitingNCT02936791
• The German ADPKD Tolvaptan Treatment RegistryRecruitingNCT02497521
• PKD Clinical and Translational Core StudyRecruitingNCT01873235
• ARPKD Database StudyRecruitingNCT01401998
• Polycystic Kidney Disease Data RepositoryRecruitingNCT00792155
• Effect of Beetroot Juice on Reducing Hypertension in Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT05401409Not applicableResults posted
• Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303TerminatedNCT05208866Phase 3Results posted
• A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)TerminatedNCT04578548Phase 2Results posted
• Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney DiseaseTerminatedNCT04152837Phase 3Results posted
• Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney DiseaseTerminatedNCT04064346Phase 3Results posted
• A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCONTerminatedNCT03918447Phase 3Results posted
• An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)TerminatedNCT03749447Phase 3Results posted
• A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD PatientsTerminatedNCT03523728Phase 2/3Results posted
• The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT03487913Phase 2Results posted
• A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIXCompletedNCT03366337Phase 2Results posted
• Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT03342742Not applicableResults posted
• Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKDCompletedNCT03203642Phase 2Results posted
• Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)CompletedNCT02964273Phase 3Results posted
• Feasibility Study of Metformin Therapy in ADPKDCompletedNCT02903511Phase 2Results posted
• Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT02697617Phase 2Results posted
• Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT02656017Phase 2Results posted
• Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKDCompletedNCT02494141Phase 4Results posted
• Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT02251275Phase 3Results posted
• Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT02225860Phase 2/3Results posted
• Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT02160145Phase 3Results posted
• HALT Progression of Polycystic Kidney Disease Study BCompletedNCT01885559Phase 3Results posted
• Pasireotide LAR in Severe Polycystic Liver DiseaseCompletedNCT01670110Phase 2Results posted
• A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT01559363Phase 1/2Results posted
• 8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT01451827Phase 2Results posted
• Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT01336972Phase 2Results posted
• A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]CompletedNCT01280721Phase 3Results posted
• Bosutinib For Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT01233869Phase 2Results posted
• Tolvaptan Extension Study in Participants With ADPKDCompletedNCT01214421Phase 3Results posted
• Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKDCompletedNCT01210560Phase 2Results posted
• A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]CompletedNCT01022424Phase 3Results posted
• Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to TherapyTerminatedNCT00920309Phase 2/3Results posted
• A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]CompletedNCT00841568Phase 2Results posted
• High Water Intake to Slow Progression of Polycystic Kidney DiseaseCompletedNCT00784030Not applicableResults posted
• Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT00456365Phase 3Results posted
• Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT00428948Phase 3Results posted
• Octreotide in Severe Polycystic Liver DiseaseCompletedNCT00426153Phase 2/3Results posted
• Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT00414440Phase 4Results posted
• Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT00413777Phase 2Results posted
• Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT00286156Phase 1/2Results posted
• HALT Progression of Polycystic Kidney Disease Study ACompletedNCT00283686Phase 3Results posted
• Descriptive Analysis of Preimplantation Genetic Test (PGT)in Couples With Polycystic Kidney Disease (PKD). In the ADPKD Subgroup Evaluation of Outcomes and Complications Comparing Couples in Which the Father is Affected With Couples in Which the Mother is AffectedCompletedNCT07310641
• Effects of Exogenous Ketosis on Proteinuria and Renal FunctionCompletedNCT06867471Not applicable
• Artificial Intelligence-based Image Processing Methods to Advance the Characterization of Polycystic Kidney DiseaseActive, not recruitingNCT06688981
• EXOME SEQUENCING IN MEDULLARY SPONGE KIDNEYActive, not recruitingNCT06418230
• Study of Tamibarotene in Patients With ADPKDActive, not recruitingNCT06289998Phase 2
• Genetic Testing in Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT06085807
• Study and Management of Cystic Complications in Autosomal Dominant Polycystic Kidney DiseaseActive, not recruitingNCT06036992
• Thyroid Hormones in ADPKDCompletedNCT05646420Not applicable
• A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT05521191Phase 1
• Assessment of Treatment With Laparoscopic Fenestration or Aspiration Sclerotherapy for Large Symptomatic Hepatic CystsStatus unknownNCT05500157Not applicable
• KidneYou - Innovative Digital TherapyCompletedNCT05286632Not applicable
• Treatment of Vascular Stiffness in ADPKDCompletedNCT05228574Phase 4
• The Association Between Skeletal Muscle Mass and Severity of Polycystic Liver Disease and Polycystic Kidney DiseaseStatus unknownNCT05215964
• Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium AdministrationCompletedNCT05190744Phase 2
• To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy VolunteersCompletedNCT04908462Phase 1
• A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)WithdrawnNCT04786574Phase 3
• Establishment of the Human Intestinal and Salivary Microbiota Biobank - Kidney DiseasesCompletedNCT04689074
• Ketogenic Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT04680780Not applicable
• A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT04536688Phase 1
• Time Restricted Feeding in Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT04534985Not applicable
• PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN)CompletedNCT04407481
• The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT04363554Not applicable
• Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and SaltStatus unknownNCT04310319Not applicable
• Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT04284657Phase 2
• The Role of Endothelial Dysfunction in Adult Polycystic Kidney DiseaseCompletedNCT04023214
• ADPKD and Peritoneal Dialysis: How Anticipate Peritoneal Pressure?CompletedNCT03970018
• Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney DiseaseCompletedNCT03949894Phase 4
• Outcome of Autosomal Dominant Polycystic Kidney Disease Patients on Peritoneal Dialysis: a National Retrospective Study Based on Two French Registries (the French Language Peritoneal Dialysis Registry and the French Renal Epidemiology and Information Network).CompletedNCT03948113
• Evaluation of Nephrectomy Specimen for Intracranial Aneurysm Development in ADPKDCompletedNCT03889392
• Dietary Intervention in ADPKD on TolvaptanCompletedNCT03858439Not applicable
• Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKDCompletedNCT03803124Phase 3
• Metformin vs Tolvaptan for Treatment of Autosomal Dominant Polycystic Kidney DiseaseStatus unknownNCT03764605Phase 3
• Evaluation of Iliac and Renal Artery for Mechanism of Intracranial Aneurysm in ADPKDStatus unknownNCT03726463
• ADPKD Alterations in Hepatic Transporter FunctionCompletedNCT03717883
• Lixivaptan in a Single Subject With Intractable Pain Due to Polycystic Kidney DiseaseNo longer availableNCT03717181
• Research Into the Molecular Bases of a New Phenotype Combining Premature White Hair, Polycystic Kidney Disease, Aortic Dilation/Dissection and LymphopeniaCompletedNCT03651388
• Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney DiseaseStatus unknownNCT03596957Phase 4
• Tolvaptan-Octreotide LAR Combination in ADPKDCompletedNCT03541447Phase 2
• Assessment of Longitudinal Changes in Endothelial Function and Oxidative Stress in Normotensive Patients With ADPKDCompletedNCT03493802

← Polycystic Kidney Diseases overview